

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MOS HOUSE GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1653)

(1) APPOINTMENT OF DIRECTOR AND BOARD COMMITTEE MEMBER;

AND

(2) CHANGE IN COMPOSITION OF BOARD COMMITTEES

(1) APPOINTMENT OF DIRECTOR AND BOARD COMMITTEE MEMBER

The Board announces that Dr. Lam, Lee G., BBS, JP has been appointed as an independent non-executive Director, the chairman of the corporate governance committee and a member of the audit committee and the nomination committee of the Company respectively with effect from 1 October 2023.

(2) CHANGES IN THE COMPOSITION OF THE NOMINATION COMMITTEE, THE CORPORATE GOVERNANCE COMMITTEE, THE AUDIT COMMITTEE AND THE REMUNERATION COMMITTEE

Mr. Hui Chun Tak, PDSM has been appointed as the chairman of the remuneration committee with effect from 1 October 2023. The composition of the audit committee, the remuneration committee, the nomination committee and the corporate governance committee of the Company will be changed respectively as follows on 1 October 2023:

The Audit Committee:

Mr. Woo King Hang, JP (*chairman*)

Mr. Hui Chun Tak, PDSM

Dr. Lam, Lee G., BBS, JP

The Remuneration Committee:

Mr. Hui Chun Tak, PDSM (*chairman*)

Ms. Tsui To Fei

Mr. Woo King Hang, JP

The Nomination Committee:

Mr. Simon Tso (*chairman*)

Mr. Hui Chun Tak, PDSM

Dr. Lam, Lee G., BBS, JP

The Corporate Governance Committee:

Dr. Lam, Lee G., BBS, JP (*chairman*)

Mr. Woo King Hang, JP

Mr. Hui Chun Tak, PDSM

(1) APPOINTMENT OF DIRECTOR AND BOARD COMMITTEE MEMBERS

The Board announces that Dr. Lam, Lee G., BBS, JP has been appointed as an independent non-executive Director, the chairman of the corporate governance committee and a member of the audit committee and nomination committee of the Company respectively with effect from 1 October 2023.

Biographical details of the newly appointed Director referred to above are set out as follows:

Dr. Lam, Lee G., BBS, JP (“**Dr. Lam**”) has extensive international experience in general management, strategy consulting, policy advocacy, corporate governance, direct investment, investment banking and asset management. He started his career in Canada at Bell-Northern Research (the research and development arm of Nortel Networks Corporation) and Bell Canada, and later he returned to Hong Kong to serve as a general manager of Hongkong Telecom, vice president of Greater China of the international management consulting firm A.T. Kearney Inc., executive director of Singapore Technologies Telemedia Pte. Ltd. (a member of Temasek Holdings Limited), vice chairman and chief operating officer of Investment Banking Division of BOC International Holdings Limited (the international investment banking arm of the Bank of China group), the chief executive officer, executive director and vice chairman of the board of Chia Tai Enterprises International Limited (now known as C.P. Lotus Corporation) of multinational conglomerate C. P. Group, senior executive vice president of C.P. Group, non-executive chairman – Hong Kong and ASEAN Region of Macquarie Infrastructure and Real Assets (Hong Kong) Limited, senior advisor – Asia, Macquarie Capital (Hong Kong) Limited, non-executive chairman – Greater China and ASEAN Region of Macquarie Infrastructure and Real Assets (Hong Kong) Limited and chief advisor – Asia of Macquarie Infrastructure and Real Assets (Hong Kong) Limited and senior advisor of Macquarie Group Asia.

Dr. Lam was Chairman of Hong Kong Cyberport, a member of the Committee on Innovation, Technology and Re-Industrialization and the Sir Murray MacLehose Trust Fund Investment Advisory Committee of the Hong Kong Special Administrative Region Government (“**HKSAR Government**”). He is a member of the Chief Executive’s Policy Unit Expert Group, the Green Technology and Finance Development Committee, the Governance Committee of the Hong Kong Growth Portfolio and the Development Bureau Common Spatial Data Advisory Committee of the HKSAR Government, and convenor of the Panel of Advisors on Building Management Disputes of the HKSAR

Government Home Affairs Department. He is also a Hong Kong accounting advisory expert of the PRC Ministry of Finance, a member of the Consultative Committee on Guangdong-Hong Kong Co-operation (Guangzhou Nansha), the Belt and Road and Greater Bay Area Committee of the Hong Kong Trade Development Council, and the Court of the City University of Hong Kong, chair of the United Nations Economic and Social Commission for Asia and the Pacific Sustainable Business Network, president of Hong Kong-ASEAN Economic Cooperation Foundation, chairman of the Innovation and Technology Committee of the Belt and Road General Chamber of Commerce, vice chairman of Pacific Basin Economic Council, and a board member and chairman of the Permanent Commission on Economic and Financial Issues of the World Union of Small and Medium Enterprises.

Dr. Lam holds a bachelor of science and mathematics (BSc Hons), a master of systems science and an MBA from the University of Ottawa in Canada, a post-graduate diploma in public administration from Carleton University in Canada, a post-graduate diploma in English and Hong Kong Law and an LLB (Hons) in law from Manchester Metropolitan University in the United Kingdom (“UK”), a LLM in law from the University of Wolverhampton in the UK, a Postgraduate Certificate in Laws (PCLL) in law from the City University of Hong Kong, an MPA and a PhD from the University of Hong Kong. Dr. Lam is a former member of the Bar of Hong Kong, a solicitor of the High Court of Hong Kong, an accredited mediator of the Centre for Effective Dispute Resolution (CEDR), a fellow of the Hong Kong Institute of Arbitrators, the Hong Kong Institute of Directors, and Certified Management Accountants (CMA) Australia, an international affiliate of the Hong Kong Institute of Certified Public Accountants (HKICPA), an honorary fellow of Certified Public Accountants (CPA) Australia, the Hong Kong Institute of Facility Management and the University of Hong Kong School of Professional and Continuing Education, and a distinguished fellow of the Hong Kong Innovative Technology Development Association.

Dr. Lam is an executive director of Hong Kong Aerospace Technology Group Limited (Stock Code: 1725, formerly known as Eternity Technology Holdings Limited, re-designated from non-executive director on 3 January 2022), the shares of which are listed on the Main Board of The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”). He is an independent non-executive director of each of CSI Properties Limited (Stock Code: 497), Vongroup Limited (Stock Code: 318), Mei Ah Entertainment Group Limited (Stock Code: 391), Elife Holdings Limited (Stock Code: 223, formerly known as Sino Resources Group Limited), Haitong Securities Company Limited, (Stock Code: 6837, it is also listed on the Shanghai Stock Exchange, Stock Code: 600837), Hang Pin Living Technology Company Limited (Stock Code: 1682), Kidsland International Holdings Limited (Stock Code: 2122), Greenland Hong Kong Holdings Limited (Stock Code: 337) and Huarong International Financial Holdings Limited (Stock Code: 993), RENHENG Enterprise Holdings Limited (Stock Code: 3628) and Sinohope Technology Holdings Limited (Stock code: 1611, formerly known as New Huo Technology Holdings Limited) ; and a non-executive director of each of Sunwah Kingsway Capital Holdings Limited (Stock Code: 188), China LNG Group Limited (Stock Code: 931) and Mingfa Group (International) Company Limited (Stock Code: 846, re-designated from independent non-executive director on 23 April 2020), the shares of all of which are listed on the Stock Exchange. He is also an independent non-executive director of Asia-Pacific Strategic Investments Limited (Stock Code: 5RA,

formerly known as China Real Estate Group Ltd.), Thomson Medical Group Limited (Stock Code: A50) and Alset International Limited (Stock Code: 40V, formerly known as Singapore eDevelopment Limited), re-designated from non-executive director on 2 July 2020), the shares of all of which are listed on the Singapore Exchange. Dr. Lam is an independent non-executive director of AustChina Holdings Limited (Stock Code: AUH, formerly known as Coalbank Limited), whose shares are listed on the Australian Securities Exchange, and a non-executive director of Jade Road Investments Limited (Stock Code: JADE, formerly known as Adamas Finance Asia Limited), whose shares are listed on the London Securities Exchange.

In the past three years, Dr. Lam was a non-executive director of National Arts Group Holdings Limited (Stock Code: 8228, formerly known as National Arts Entertainment and Culture Group Ltd.) up to July 2022, Tianda Pharmaceuticals Limited (Stock Code: 455) up to August 2021, and China Shandong Hi-Speed Financial Group Limited (Stock Code: 412, now known as Shandong Hi-Speed Holdings Group Limited) up to May 2020, and he was also an independent non-executive director of Aurum Pacific (China) Group Limited (Stock Code: 8148) up to March 2021 and Huarong Investment Stock Corporation Limited (Stock Code: 2277, which was privatized on 12 November 2020) up to December 2020, the shares of all of which are listed on the Stock Exchange. He was an independent non-executive director of each of Beverly JCG Ltd. (listed on the Singapore Exchange, Stock Code: VFP, formerly known as JCG Investment Holdings Ltd.) up to April 2023 and Top Global Limited (Stock Code: BHO), up to August 2021 (delisted on the Singapore Exchange since August 2021), Sunwah International Limited (Stock Code: SWH, listed on the Toronto Stock Exchange) up to June 2021 and TMC Life Sciences Berhad (Stock Code: 0101, listed on the Bursa Malaysia) up to 31 May 2023.

Dr. Lam had entered into a service contract with the Company for the period from 1 October 2023 to 30 September 2024 (both dates inclusive), subject to the retirement and re-election provisions in the amended and restated articles of association of the Company unless and until terminated by either party giving to the other not less than 1 month's prior notice in writing to determine the same. Pursuant to the service contract, Dr. Lam will be entitled to receive an annual director's fee of HK\$240,000, payable monthly in arrears in equal amount of HK\$20,000.

Save as disclosed above, as at the date of this announcement, Dr. Lam (i) does not hold any other positions with the Company or other members of the Group, (ii) does not hold any directorships in other public companies the securities of which are listed on any securities market in the Hong Kong Special Administrative Region of the People's Republic of China or overseas in the three years immediately preceding the date of this announcement, (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company, and (iv) does not have any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong). Dr. Lam has confirmed that he has met the independence criteria as set out in Rule 3.13 of the Listing Rules.

The Board noted that Dr. Lam holds directorships in more than seven listed companies (including the Company). However, the Board is of the view that Dr. Lam would be able to devote sufficient time to the Board on the following basis: (i) according to the publicly available information, Dr. Lam has a high attendance rate for general meetings, board meetings and board committee meetings of the other listed companies of which he is a director; (ii) as an independent non-executive director or a non-executive director of the Company and other listed companies, Dr. Lam is mainly involved in the provision of strategic and independent advice to the management and review of the companies' businesses from an independent perspective instead of participating in the day-to-day management of the companies; (iii) Dr. Lam has undertaken to devote sufficient time to attend to the affairs of the Company; and (iv) Dr. Lam has over 20 years of experience as a director of listed companies since 2001, and his background, experience and qualifications indicate that Dr. Lam can manage his time to meet the needs. Taking into account the above factors, the Board is of the view that notwithstanding that Dr. Lam holds directorships in more than seven listed companies, he would be able to devote sufficient time to fulfill his duties as an independent non-executive Director of the Company.

Save as disclosed above, there is no other information in relation to the appointment of Dr. Lam which is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to welcome Dr. Lam to join the Company.

(2) CHANGES IN COMPOSITION OF BOARD COMMITTEES

Mr. Hui Chun Tak, PDSM has been appointed as the chairman of the remuneration committee with effect from 1 October 2023. The composition of the audit committee, the remuneration committee, the nomination committee and the corporate governance committee of the Company will be changed respectively as follows on 1 October 2023:

The Audit Committee:

Mr. Woo King Hang, JP (*chairman*)

Mr. Hui Chun Tak, PDSM

Dr. Lam, Lee G., BBS, JP

The Remuneration Committee:

Mr. Hui Chun Tak, PDSM (*chairman*)

Ms. Tsui To Fei

Mr. Woo King Hang, JP

The Nomination Committee:

Mr. Simon Tso (*chairman*)

Mr. Hui Chun Tak, PDSM

Dr. Lam, Lee G., BBS, JP

The Corporate Governance Committee:

Dr. Lam, Lee G., BBS, JP (*chairman*)

Mr. Woo King Hang, JP

Mr. Hui Chun Tak, PDSM

By Order of the Board
MOS House Group Limited
Simon Tso
Chairman

Hong Kong, 29 September 2023

As at the date of this announcement, the Board comprises of two executive Directors, namely Mr. Simon Tso and Ms. Tsui To Fei and two independent non-executive Directors, namely Mr. Woo King Hang, JP and Mr. Hui Chun Tak, PDSM.